TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00934934
Drug: anidulafungin
Normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TBA
Study: NCT02785003
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All individuals randomized to the experimental arm of the trial will receive ketamine therapy at a rate of 2 mcg/kg/hr dosed based on ideal body weight.
Study: NCT02785003
Drug: Alvimopan
Normalized name: Alvimopan
DrugBank: Alvimopan (DB06274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients enrolled into the trial will be screened for eligibility for alvimopan utilization. Only in circumstances where patients are not on outpatient opioid medications and where they have not received any at time of arrival will alvimopan be administered. It will be given at least 30 minutes prior to surgery.
Study: NCT00881088
Drug: Nadroparin
Normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nadroparin 0,3 cc once daily during immobilization period
Study: NCT00881088
Drug: Fondaparinux
Normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fondaparinux 2,5 mg daily during immobilization period
Study: NCT00524342
Drug: Oprelvekin, Interleukin 11, IL-11
DrugBank: Oprelvekin (DB00038)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 micrograms/kg by subcutaneous injection once daily for four days, then once daily on day 1-7 during each of six consecutive menstrual cycles
Study: NCT04140318
Drug: sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab 200mg, iv, 30-60min, q3w;
Study: NCT04140318
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel: 125 mg/m2 iv d1、d8, q3w
Study: NCT02592356
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02592356
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03514342
Drug: 0.75% ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placement of 25 to 30 ml of 0.75% ropivacaine around the 5th to 7th cervical nerve roots
Study: NCT01537861
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01537861
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01537861
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01537861
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01537861
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01537861
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01537861
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01940471
Drug: TDF
Normalized name: moxetumomab pasudotox-tdfk
DrugBank: Moxetumomab pasudotox (DB12688)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 300 mg tablet administered orally once daily
Study: NCT01532141
Drug: Rasagiline
Normalized name: Rasagiline
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mg rasagiline (single-dose)
Study: NCT01735409
Drug: ABX + DDP
Normalized name: DDP-200
DrugBank: DDP-200 (DB05919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABX 260 mg/m2 day 1 + DDP 75mg/m2 day 1
Study: NCT01735409
Drug: ABX + DDP
Normalized name: DDP-200
DrugBank: DDP-200 (DB05919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABX 140 mg/m2 day 1,8 + DDP 75mg/m2 day 1
Study: NCT01735409
Drug: ABX + DDP
Normalized name: DDP-200
DrugBank: DDP-200 (DB05919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABX 100 mg/m2 day 1,8,15 + DDP 75mg/m2 day 1
Study: NCT00383656
Drug: GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 ng/kg GnRH IV
Study: NCT00343278
Drug: Valaciclovir Hydrochloride
Normalized name: Valaciclovir hydrochloride
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02337309
Drug: SF1126
Normalized name: SF1126
DrugBank: SF1126 (DB05210)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SF1126 in IV form with be given to patients on this study.
Study: NCT00783861
Drug: Lactic Acid
Normalized name: Lactic Acid
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactic Acid (Dermacyd Femina)
Study: NCT01974297
Drug: Atorvastatin 10mg, fenofibric acid 135mg
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 10mg, fenofibric acid 135mg/day PO for 12 weeks
Study: NCT01974297
Drug: atorvastatin 20mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 20MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 20mg/day PO for 12weeks
Study: NCT00021528
Drug: citalopram
Normalized name: Citalopram
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00021528
Drug: BuproprionSR
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00021528
Drug: buspirone
Normalized name: Buspirone
DrugBank: Buspirone (DB00490)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00021528
Drug: Lithium
Normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00021528
Drug: mirtazapine
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00021528
Drug: nortriptyline
Normalized name: Nortriptyline
DrugBank: Nortriptyline (DB00540)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00021528
Drug: sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00021528
Drug: tranylcypromine
Normalized name: Tranylcypromine
DrugBank: Tranylcypromine (DB00752)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00021528
Drug: VenlafaxineXR
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00021528
Drug: T3 (Triiodothyronine)
Normalized name: T3
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00698230
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03921294
Drug: Emicizumab
Normalized name: Emicizumab
DrugBank: Emicizumab (DB13923)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bispecific monoclonal antibody binding to activated Factor IX and Factor X
Study: NCT01263860
Drug: Peginterferon alfa2a
Normalized name: ribavirin/peginterferon alfa2a 200 mg (1 tablet)-180 mcg MISCELL COMBINATION PACKAGE (EA)
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
Study: NCT01263860
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
Study: NCT01263860
Drug: Peginterferon alfa2a
Normalized name: ribavirin/peginterferon alfa2a 200 mg (1 tablet)-180 mcg MISCELL COMBINATION PACKAGE (EA)
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
Study: NCT01263860
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
Study: NCT03966560
Drug: Brimonidine Tartrate
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brimonidine tartrate 0.15% 1 eye drop, every day for 6-months
Study: NCT03966560
Drug: Dorzolamide (as Dorzolamide Hydrochloride) 20 Mg/mL and Timolol (as Timolol Maleate) 5 Mg/mL Eye Drops
Normalized name: Dorzolamide (as dorzolamide hydrochloride) 20 mg/mL and timolol (as timolol maleate) 5 mg/mL eye drops
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dorzolamide and timolol fixed combination 2 eye drops, every day for 6 months
Study: NCT03966560
Drug: Brinzolamide/Timolol 10 MG/1 ML-5 MG/1 ML Ophthalmic Suspension
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brinzolamide and timolol fixed combination 2 eye drops, every day for 6 months
Study: NCT03966560
Drug: Travoprost and Timolol
Normalized name: Travoprost
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Travoprost and Timolol fixed combination 1 eye drop, every day for 6 months
Study: NCT03966560
Drug: Bimatoprost and Timolol
Normalized name: Bimatoprost and timolol only product
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bimatoprost and Timolol fixed combination 1 eye drop, every day for 6 months
Study: NCT03966560
Drug: Latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost 0.005% 1 eye drop, every day for 6 months
Study: NCT04828720
Drug: ozonated oil
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients in ozone group were asked to visit the clinic on a daily basis through the first week and have their allocated therapeutic medication applied to their particular palatal donor site wounds. The wounds were coated with 2 ml ozonated oil per day, with a concentration of 15 µg of ozone/ml of olive oil. Moreover, palatal wounds in control group were managed by compressing the donor site with gauze and periodontal pack was placed. Patients in ozone group used a soft stent to protect the palatal donor wound site and to retain the tested oils in the post harvested palatal wounds. Patients were instructed firmly not to shatter the stent for 1 week. The stent was removed and reseated only by the operator during the application of medications and collection of smears. One week postoperatively, the protective stents were discontinued.
Study: NCT03222765
Drug: Placebo, metformin, linagliptin, linagliptin + metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02803528
Drug: MTA
Normalized name: HMTA
DrugBank: 5'-S-methyl-5'-thioadenosine (DB02282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTA is going to be used as the direct pulp capping material in the second group
Study: NCT01622504
Drug: Naloxone hydrochloride solution for injection with mucosal atomization device
Normalized name: naloxone hydrochloride Injectable Solution
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg single dose administered intranasally
Study: NCT01535547
Drug: isavuconazole
Normalized name: Isavuconazole
DrugBank: Isavuconazole (DB11633)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01535547
Drug: tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT00488722
Drug: Zoladex
Normalized name: Zoladex
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04453371
Drug: Tissue plasminogen activator
Normalized name: Tissue plasminogen activator
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the study group, tPA (Alteplase) 25 mg i/v over 2 hours, followed by a 25 mg tPA infusion over the subsequent 22 hours. After the end of thrombolytic therapy, unfractionated heparin is administered i/v at a starting dose of 10 units / kg per hour. The target value of PTT is 40C-50C.~In both groups patient's transfer from the heparin infusion to the introduction of low-molecular-weight heparins is performed after normalization of the D-dimer level.
Study: NCT03976544
Drug: Estradiol Valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol valerate will be started in the beginning of the menstrual cycle in order to induce proliferation of the endometrium.
Study: NCT02600286
Drug: EllaOne
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * 5 mg/per os of EllaOne every day through 12 months.~* 10 mg/per os of EllaOne every day through 12 months.~* EllaOne placebo/per os every day through 12 months.
Study: NCT00152035
Drug: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04453371
Drug: Ringer solution
DrugBank: COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection (DB15845)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the control group, an equivalent amount of Ringer's solution is administered. After 24 hours, the heparin infusion gets started, similar the described for study group.~In both groups patient's transfer from the heparin infusion to the introduction of low-molecular-weight heparins is performed after normalization of the D-dimer level.
Study: NCT00259649
Drug: eletriptan
Normalized name: Eletriptan
DrugBank: Eletriptan (DB00216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral eletriptan 20 mg three times a day beginning 2 days before the expected onset of menstrual flow and continued for a total of 6 days
Study: NCT00527657
Drug: Lomustine
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose 30 mg/m\^2 by mouth daily on Day 1 and 29.
Study: NCT00527657
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 75 mg/m\^2 by mouth daily on Days 1 to 42.
Study: NCT00527657
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m\^2 by mouth daily.
Study: NCT03136666
Drug: Nifedipine gastrointestinal therapeutic system (GITS) (Adalat LA, BAY a1040) + Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan and nifedipine were administered together as loose combination with 240 mL non-sparkling water in the morning after a fasting period of at least 10 hours.
Study: NCT04126083
Drug: Lofexidine Oral Tablet
Normalized name: lofexidine Oral Tablet
DrugBank: Lofexidine (DB04948)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lofexidine 0.54 mg 4 times daily
Study: NCT00815763
Drug: ginsenoside-Rd
Normalized name: ginsenoside
DrugBank: Ginsenoside Rd (DB19256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion ginsenoside-Rd 20 mg once a day and continued for 14 day
Study: NCT00578136
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine, 0.25%, dose amount is weight based, injection is divided per dise with rectus sheath injection or with local infiltration of the operative area.
Study: NCT03700580
Drug: P1G10
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: P1G10 containing dressing composed by 8% Polawax, 6% liquid vaseline, 0.06% butylated hydroxytoluene, 0.15% Nipagin, 5% propyleneglycol, 0.1% Nipazol, 0.1% ethylenediaminetetraacetate disodium salt, 0.03% methyl-aminopropanol-95, 0.3% Imidazolidinyl urea, 2% Cyclomethicone, 78.2% distilled water. A single batch of the formulation was made and used throughout the intervention. A sample of this preparation was used to assess the extended stability of the formulation. The formulation was dispensed into 100 g dispensers for weekly use.
Study: NCT02158182
Drug: Lactulose
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 30 ml by mouth three times daily until melena resolved, then adjusted to dose-response to obtain two to three soft stools. Duration of therapy: 7 days
Study: NCT02158182
Drug: Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 tablets (400mg) three times daily. Duration of therapy: 7 days
Study: NCT01469767
Drug: Fluocinonide cream
Normalized name: Fluocinonide Cream
DrugBank: Fluocinonide (DB01047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinonide cream 0.1% applied twice daily for 5 days.
Study: NCT02006160
Drug: dalfampridine
Normalized name: Dalfampridine
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bid
Study: NCT01029522
Drug: Atorvastatin (Lipilou)
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: treatment of dyslipidemia administration : PO, qod
Study: NCT03976544
Drug: Micronized progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: If the endometrium is considered adequately proliferated, micronized progesterone is administered and frozen-thawed blastocyst transfer will take place on the 6th day of supplementation.
Study: NCT01029522
Drug: Atorvastatin (Lipitor)
Normalized name: atorvastatin Oral Tablet [Lipitor]
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: treatment of dyslipidemia administration : PO, qod
Study: NCT01219322
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single use of sodium bicarbonate and sterile water for injection 1:1 concentration 50 cc
Study: NCT01413581
Drug: rhBSSL (recombinant human bile-salt-stimulated lipase)
Normalized name: bile salts
DrugBank: Bucelipase alfa (DB16664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhBSSL added to infant formula/pasteurized breast milk during a 4 week treatment period.
Study: NCT03447262
Drug: IVA
Normalized name: Viva
DrugBank: Adenosine (DB00640)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IVA tablet qd in the evening.
Study: NCT01223820
Drug: Capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5x nasal application in one day, 1 hour between each application
Study: NCT02548403
Drug: PEG-Asc with simethicone
Normalized name: PEG-14 dimethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure. Two packs (200 mg/10 mL each) of simethicone (400 mg) was mixed with last 500 mL of additional clear fluid.
Study: NCT00020904
Drug: ixabepilone
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00035581
Drug: poly I-poly C12U
Normalized name: poly I:C
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-400 mg IV infusions 2x/week for 24 weeks
Study: NCT02680132
Drug: Torrent's Esomeprazole Magnesium DR Capsules 40 mg
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral, cross over
Study: NCT00317720
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Loading dose = 8 mg/kg daily; maintenance dose = 6 mg/kg once per 21 day cycle.~If participant on trastuzumab at time of registration, loading dose deferred and received maintenance dose (6 mg/kg every 3 weeks). If the last trastuzumab dose was given 1 week (for participants receiving 2 mg/kg/week), or 3 weeks before registration (for participants receiving 6 mg/kg every 3 weeks), a loading dose (8 mg/kg) was given followed by maintenance dose.
Study: NCT02717884
Drug: tranylcypromine
Normalized name: Tranylcypromine
DrugBank: Tranylcypromine (DB00752)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TCP p.o., daily either 20, 40\*\*, 60\*\*, 80\*\* mg/day, (28d/cycle)~\*\*TCP doses will be slowly increased during cycle 1 and slowly decreased at end of treatment (for details see study protocol)
Study: NCT02717884
Drug: all-trans retinoic acid
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 45mg/m2 (days 10-28), CAVE: ATRA will be administered without interruption until inclusively cycle 3. At the beginning of the cycle 4 a nine-day break corresponding to the first nine days of the AraC treatment will be performed, thereafter the ATRA-therapy will be continued with a nine-day interruption every fourth cycle. That means that the therapy in cycles 1, 4, 7, 10, 13 etc. In other cycles ATRA will be given without interruption
Study: NCT02717884
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40mg s.c. (days 1-10)
Study: NCT00553280
Drug: pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
Study: NCT05681247
Drug: ezetimibe tablet
Normalized name: Ezetimibe Tablets
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The subjects randomly received single oral administration of ezetimibe tablet 10 mg
Study: NCT05681247
Drug: ezetimibe tablet(Ezetrol ®)
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The subjects randomly received single oral administration of ezetimibe tablet (Ezetrol ®) 10 mg.
Study: NCT04349592
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine 200 mg tablet oral, one tablet three times a day for 7 days
Study: NCT00003111
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003111
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003111
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003111
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01395875
Drug: Fluticasone Propionate / Salmeterol Xinafoate Combination (FSC)
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: COPD patients receiving fluticasone propionate/salmeterol xinafoate combination (FSC) 250/50mcg
Study: NCT00001862
Drug: Enbrel
Normalized name: Enbrel
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02697331
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: women will receive progesterone vaginal pesarries containing 200mg of progesterone twice daily . it will be used by the patient as one vaginal pessary per vagina twice per day .~women will be showed how to use tablets . medication will be started at 20 -24 weeks and stopped at 36+6 weeks